FocalTherics (NASDAQ:FOCL) Given Average Rating of “Hold” by Analysts

FocalTherics (NASDAQ:FOCL) has been given an average recommendation of “Hold” by the five ratings firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, one has assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $7.75.

Several research firms have weighed in on FOCL. Weiss Ratings reissued a “sell (d-)” rating on shares of FocalTherics in a report on Monday, August 17th. Wall Street Zen downgraded FocalTherics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Mizuho set a $15.00 price objective on shares of FocalTherics and gave the company an “outperform” rating in a research note on Friday, July 17th. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of FocalTherics in a report on Tuesday, August 25th. Finally, Piper Sandler restated a “neutral” rating and set a $4.00 target price on shares of FocalTherics in a research report on Friday, August 14th.

Insiders Place Their Bets

In related news, Director David R. Horn bought 10,000 shares of FocalTherics stock in a transaction that occurred on Friday, August 14th. The shares were purchased at an average price of $4.75 per share, with a total value of $47,500.00. Following the purchase, the director owned 10,000 shares in the company, valued at $47,500. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Joshua Levine bought 10,000 shares of FocalTherics stock in a transaction that occurred on Friday, August 14th. The stock was bought at an average cost of $4.75 per share, for a total transaction of $47,500.00. Following the purchase, the director owned 45,000 shares in the company, valued at $213,750. This represents a 28.57% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders acquired 116,000 shares of company stock valued at $551,000. Corporate insiders own 10.10% of the company’s stock.

Hedge Funds Weigh In On FocalTherics

A number of institutional investors have recently made changes to their positions in the stock. SmartHarvest Portfolios LLC purchased a new stake in shares of FocalTherics in the first quarter valued at $38,000. Lido Advisors LLC purchased a new stake in FocalTherics during the 1st quarter worth about $40,000. Kovack Advisors Inc. acquired a new position in FocalTherics in the 4th quarter valued at about $53,000. Leonteq Securities AG acquired a new position in FocalTherics in the 4th quarter valued at about $313,000. Finally, Flax Pond Capital LLC purchased a new position in FocalTherics in the 4th quarter valued at about $2,623,000. 62.74% of the stock is owned by institutional investors and hedge funds.

FocalTherics Price Performance

Shares of NASDAQ:FOCL opened at $4.15 on Tuesday. The stock has a market cap of $155.75 million, a price-to-earnings ratio of -4.03 and a beta of -0.07. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.60 and a quick ratio of 1.38. The stock’s 50 day moving average price is $5.20. FocalTherics has a 12 month low of $1.75 and a 12 month high of $6.40.

FocalTherics (NASDAQ:FOCL) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.19). The firm had revenue of $13.20 million during the quarter. FocalTherics had a negative net margin of 56.26% and a negative return on equity of 248.00%. On average, equities analysts anticipate that FocalTherics will post -0.82 earnings per share for the current year.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.